特瑞普利单抗治疗转移性恶性黑色素瘤1例  

A case of metastatic malignant melanoma treated with toripalimab

作　　者：徐兰 叶刚[1] Xu Lan;Ye Gang(Department of Gastroenterology,The First Affiliated Hospital of Jinan University,Guangzhou 510630,China)

机构地区：[1]暨南大学附属第一医院消化内科,广州510630

出　　处：《国际医药卫生导报》2024年第6期1025-1027,共3页International Medicine and Health Guidance News

基　　金：广东省基础与应用基础研究基金(2023A1515011617)。

摘　　要：恶性黑色素瘤发病率低,致死率高、生存期短,早期以手术治疗为主,晚期多予以应用化学药物治疗,但有效率不高。免疫治疗在多种恶性肿瘤治疗中取得进阶性、突破性发展,同时也在临床中被证实可延长恶性黑色素瘤患者的生存时间。本文分享暨南大学附属第一医院1例特瑞普利单抗治疗转移性恶性黑色素瘤并获得较佳疗效的病例。The incidence of malignant melanoma is low,the mortality is high,and the survival time is short.In the early stage,surgery is the main treatment;in the late stage,chemical drugs are mostly used,but the effective rate is not high.Immunotherapy has achieved advanced and breakthrough development in the treatment of a variety of malignant tumors,and has also been proved to prolong the survival time of malignant melanoma patients in clinical practice.This article is to share a case of metastatic malignant melanoma treated with toripalimab who has achieved good efficacy in the First Affiliated Hospital of Jinan University.

关 键 词：恶性黑色素瘤 特瑞普利单抗 免疫治疗 

分 类 号：R739.5[医药卫生—肿瘤]